BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 23698198)

  • 1. High-dose methotrexate in adult oncology patients: a case-control study assessing the risk association between drug interactions and methotrexate toxicity.
    Chan AJ; Rajakumar I
    J Oncol Pharm Pract; 2014 Apr; 20(2):93-9. PubMed ID: 23698198
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of incidence and risk factors for high-dose methotrexate-induced nephrotoxicity.
    Wiczer T; Dotson E; Tuten A; Phillips G; Maddocks K
    J Oncol Pharm Pract; 2016 Jun; 22(3):430-6. PubMed ID: 26152702
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Delayed methotrexate elimination: Incidence, interaction with antacid drugs, and clinical consequences?
    Ranchon F; Vantard N; Henin E; Bachy E; Sarkozy C; Karlin L; Bouafia-Sauvy F; Gouraud A; Schwiertz V; Bourbon E; Baudouin A; Caffin AG; Vial T; Salles G; Rioufol C
    Hematol Oncol; 2018 Apr; 36(2):399-406. PubMed ID: 28983943
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Delayed methotrexate clearance in osteosarcoma patients treated with multiagent regimens of neoadjuvant chemotherapy.
    Bacci G; Ferrari S; Longhi A; Forni C; Loro L; Beghelli C; Tremosini M; Versari M
    Oncol Rep; 2003; 10(4):851-7. PubMed ID: 12792734
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Severe intoxication with methotrexate possibly associated with concomitant use of proton pump inhibitors.
    Santucci R; Levêque D; Kemmel V; Lutz P; Gérout AC; N'guyen A; Lescoute A; Schneider F; Bergerat JP; Herbrecht R
    Anticancer Res; 2010 Mar; 30(3):963-5. PubMed ID: 20393020
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High-dose methotrexate with or without whole brain radiotherapy for primary CNS lymphoma (G-PCNSL-SG-1): a phase 3, randomised, non-inferiority trial.
    Thiel E; Korfel A; Martus P; Kanz L; Griesinger F; Rauch M; Röth A; Hertenstein B; von Toll T; Hundsberger T; Mergenthaler HG; Leithäuser M; Birnbaum T; Fischer L; Jahnke K; Herrlinger U; Plasswilm L; Nägele T; Pietsch T; Bamberg M; Weller M
    Lancet Oncol; 2010 Nov; 11(11):1036-47. PubMed ID: 20970380
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Outcomes Associated with Reducing the Urine Alkalinization Threshold in Patients Receiving High-Dose Methotrexate.
    Drost SA; Wentzell JR; Giguère P; McLurg DL; Sabloff M; Kanji S; Nguyen TT
    Pharmacotherapy; 2017 Jun; 37(6):684-691. PubMed ID: 28394433
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Renal dysfunction during and after high-dose methotrexate.
    Green MR; Chamberlain MC
    Cancer Chemother Pharmacol; 2009 Mar; 63(4):599-604. PubMed ID: 18504579
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of Levetiracetam on Time to High-Dose Methotrexate Clearance in Patients With Hematologic Malignancies.
    Lou U; Kwok J; Nguyen TA; Zhou A; Luk SO
    J Clin Pharmacol; 2020 Mar; 60(3):324-330. PubMed ID: 31729053
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A population pharmacokinetic/pharmacodynamic model of methotrexate and mucositis scores in osteosarcoma.
    Johansson ÅM; Hill N; Perisoglou M; Whelan J; Karlsson MO; Standing JF
    Ther Drug Monit; 2011 Dec; 33(6):711-8. PubMed ID: 22105588
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Weekly methotrexate (50mg/m(2)) without dose escalation as a primary regimen for low-risk gestational trophoblastic neoplasia.
    Kang WD; Choi HS; Kim SM
    Gynecol Oncol; 2010 Jun; 117(3):477-80. PubMed ID: 20347479
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Extended duration of prehydration does not prevent nephrotoxicity or delayed drug elimination in high-dose methotrexate infusions: a prospectively randomized cross-over study.
    Mikkelsen TS; Mamoudou AD; Tuckuviene R; Wehner PS; Schroeder H
    Pediatr Blood Cancer; 2014 Feb; 61(2):297-301. PubMed ID: 24039194
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Glucarpidase (carboxypeptidase g2) intervention in adult and elderly cancer patients with renal dysfunction and delayed methotrexate elimination after high-dose methotrexate therapy.
    Schwartz S; Borner K; Müller K; Martus P; Fischer L; Korfel A; Auton T; Thiel E
    Oncologist; 2007 Nov; 12(11):1299-308. PubMed ID: 18055849
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preventing and Managing Toxicities of High-Dose Methotrexate.
    Howard SC; McCormick J; Pui CH; Buddington RK; Harvey RD
    Oncologist; 2016 Dec; 21(12):1471-1482. PubMed ID: 27496039
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Effects of infusion duration of high-dose methotrexate on cerebrospinal fluid drug levels in lymphoma patients].
    Lin XB; Zhou NN; Li S; Cai QQ; Xia ZJ; Liao H; Gao Y; Huang HQ
    Ai Zheng; 2008 Oct; 27(10):1100-5. PubMed ID: 18851792
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hyper-alkalinization without hyper-hydration for the prevention of high-dose methotrexate acute nephrotoxicity in patients with osteosarcoma.
    Mir O; Ropert S; Babinet A; Alexandre J; Larousserie F; Durand JP; Enkaoua E; Anract P; Goldwasser F
    Cancer Chemother Pharmacol; 2010 Nov; 66(6):1059-63. PubMed ID: 20155268
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Toxic encephalopathy and delayed MTX clearance after high-dose methotrexate therapy in a child homozygous for the MTHFR C677T polymorphism.
    Müller J; Kralovánszky J; Adleff V; Pap E; Németh K; Komlósi V; Kovács G
    Anticancer Res; 2008; 28(5B):3051-4. PubMed ID: 19031955
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modified ProMACE-MOPP hybrid regimen with moderate-dose methotrexate for patients with primary CNS lymphoma.
    Yamanaka R; Morii K; Shinbo Y; Takeuchi S; Tamura T; Hondoh H; Takahashi H; Onda K; Takahashi H; Tanaka R
    Ann Hematol; 2005 Jul; 84(7):447-55. PubMed ID: 15747120
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Suspicion of drug-drug interaction between high-dose methotrexate and proton pump inhibitors: a case report - should the practice be changed?
    Ranchon F; Vantard N; Gouraud A; Schwiertz V; Franchon E; Pham BN; Vial T; You B; Bouafia F; Salles G; Rioufol C
    Chemotherapy; 2011; 57(3):225-9. PubMed ID: 21597286
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Carboxypeptidase-G2 administration after high-dose methotrexate. Treatment and drug interactions].
    Cózar Olmo JA; Martínez Colmenero C; Peláez Pleguezuelos I; Leiva Gea I; López García AB; de la Cruz Moreno J
    An Pediatr (Barc); 2009 Sep; 71(3):230-4. PubMed ID: 19617010
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.